The clinical importance of CD16a interaction with antibody Fc region is highlighted by the success of several FDA-approved cancer therapies, including rituximab (14), trastuzumab (15), and cetuximab (16), all of which rely on CD16a receptor activation to achieve their anti-tumor effects (6). This evidence concerns the gene FCGR3A and cancer.